6533b7d8fe1ef96bd1269b03
RESEARCH PRODUCT
Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma
Manuela LabbozzettaGiuseppe MontaltoNatale D'alessandroVito M. R. MuggeoPaola PomaRossana PorcasiMonica NotarbartoloLydia GiannitrapaniAda Maria FlorenaMelchiorre CervelloNicoletta VivonaLuigi Sandonatosubject
AdultLiver CirrhosisMaleMAPK/ERK pathwayCarcinoma HepatocellularSettore MED/09 - Medicina InternaSurvivinCell Cycle ProteinsPhosphatidylethanolamine Binding ProteinSettore MED/08 - Anatomia PatologicaBiologymedicine.disease_causeBiochemistryInhibitor of Apoptosis ProteinsSurvivinGeneticsmedicineHumansRNA MessengerHepatocellular carcinomaYY1RKIPMolecular BiologyTranscription factorYY1 Transcription FactorAgedAged 80 and overSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 Raf-1 Kinase Inhibitor Protein Yin Yang 1-associated proteinKinaseYY1Liver NeoplasmsNuclear ProteinsMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticLiverHepatocellular carcinomaembryonic structuresSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineFemaleSettore SECS-S/01 - StatisticaCarcinogenesisTranscription FactorsBiotechnologydescription
The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical analyses were also performed. The ratio of YY1 to RKIP mRNA was constantly profoundly inverted in the tumors compared with the adjacent nontumoral tissues. A similar result occurred frequently at protein level. Hyperactivation of YY1 in tumors was corroborated by its nuclear localization and the finding that in the tumors there were also increases in YY1AP, a YY1 coactivator not expressed in normal liver, and in survivin, as a possible target of YY1. The frequent alteration in the YY1-RKIP balance might represent a marker of malignant progression and be exploited for therapeutic interventions in HCC.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-02-22 | OMICS: A Journal of Integrative Biology |